BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,634,697

« Back to Dashboard

Summary for Patent: 4,634,697

Title: Carboxyalkenamidocephalosporins
Abstract:An antibacterial 7beta-(carboxyalkenoyl)amino-3-cephem-4-carboxylic acid represented by the following formula: ##STR1## (wherein R is aryl or a heterocyclic group; R.sup.1 is hydrogen or halogen; R.sup.2 is a single bond, alkylene, or thiaalkylene; R.sup.3 is a hydrogen atom or carboxy modifying group; R.sup.4 is hydrogen or methoxy; R.sup.5 is hydrogen or a 3-substituent of cephalosporins; R.sup.6 is a hydrogen atom or carboxy modifying group; and X is oxygen, sulfur, or sulfinyl) a pharmaceutical composition containing the same, and a method for treating a bacterial infection with the same.
Inventor(s): Hamashima; Yoshio (Kyoto, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP)
Application Number:06/711,017
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,634,697

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan58-186601Oct 04, 1983
Japan59-18563Feb 03, 1984
Japan59-100890May 18, 1984

International Patent Family for Patent: 4,634,697

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina242392► Subscribe
Austria99311► Subscribe
Australia1619488► Subscribe
Australia3330084► Subscribe
Australia575854► Subscribe
Australia601842► Subscribe
Canada1238910► Subscribe
Canada1272713► Subscribe
China1012268► Subscribe
China85101165► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: